DISCOVERY LABORATORIES INC (DSCO)
(Delayed Data from NSDQ)
$3.50 USD
-0.36 (-9.33%)
Updated Apr 18, 2016 03:59 PM ET
After-Market: $3.52 (%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Windtree Therapeutics, Inc. [DSCO]
Reports for Purchase
Showing records 1 - 20 ( 44 total )
Company: Windtree Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Windtree Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Windtree Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q14 Recap - Minor Delays, Focus on 1Q15 Aerosurf Data
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Windtree Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Windtree Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Battelle Deal Offers Validation, Burn Reduction
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Windtree Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Windtree Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q14 Recap - Progress, Albeit Slower than Expected
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Windtree Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Windtree Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q14 Recap - Surfaxin Launch Slow, But Aerosurf the Driver (3Q14 Data)
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Windtree Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Windtree Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Windtree Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Windtree Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Windtree Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Windtree Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Windtree Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Surfaxin Manufacturing Approved - Reduces Risk Profile
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Windtree Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Windtree Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Windtree Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q13 Recap - Focus on June Surfaxin Submission, 4Q13 Launch
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Windtree Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.